Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

2249 - HPV circulating tumor DNA as predictive biomarker of sustained response to chemotherapy in advanced anal carcinoma


20 Oct 2018


Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research


Translational Research

Tumour Site

Anal Cancer


Alice Bernard-Tessier


Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269


A. Bernard-Tessier1, E. Jeannot1, D. Guenat2, M. Michel3, C. Proudhon3, A. Vincent-Salomon4, I. Bièche5, J. Pierga6, B. Buecher6, E. Francois7, S. Kim8, T. André9, M. Jary8, V. Vendrely10, E. Samalin11, F. El Hajbi12, N. Baba-Hamed13, A. Meurisse14, F. Bidard15, C. Borg8

Author affiliations

  • 1 Biopathology, Institut Curie, 75005 - PARIS/FR
  • 2 Centre National De Référence Papillomavirus, CHU Besançon, Hôpital Jean Minjoz, 25030 - Besançon/FR
  • 3 Circulating Tumor Biomarkers Laboratory, Institut Curie, 75005 - PARIS/FR
  • 4 Pathology, Institut Curie, 75005 - Paris/FR
  • 5 Pharmacogenomics Unit, Institut Curie, 75005 - PARIS/FR
  • 6 Service D'oncologie Médicale, Institut Curie, 75248 cedex5 - Paris/FR
  • 7 Oncology, Centre Anticancer Antoine Lacassagne, 6100 - Nice/FR
  • 8 Medical Oncology, CHU Besançon, Hôpital Jean Minjoz, 25030 - Besançon/FR
  • 9 Medical Oncology, Hôpital Saint-Antoine, 75571 - Paris/FR
  • 10 Oncology Radiotherapy, Centre Hospitalier Universitaire de Bordeaux, Bordeaux/FR
  • 11 Medical Oncology, ICM Regional Cancer Institute of Montpellier, 34298 - Montpellier/FR
  • 12 Medical Oncology, Centre Oscar Lambret, 59020 - Lille/FR
  • 13 Medical Oncology, Groupe Hospitalier Paris Saint-Joseph, 75014 - PARIS/FR
  • 14 Methodology And Quality Of Life In Oncology Unit, CHU Besançon, Hôpital Jean Minjoz, 25030 - Besançon/FR
  • 15 Medical Oncology, Institut Curie, 75005 - Paris/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2249


The Epitopes-HPV02 single arm phase II study (NCT02402842) demonstrated the efficacy of Docetaxel, Cisplatin and 5FU as first line chemotherapy (CT) for advanced squamous cell carcinoma of the anal canal (SCCA), with a 1-year progression-free survival rate (PFS) of 47% (Kim, Lancet Oncol 2018 in press). We previously reported the validity of HPV ctDNA detection and its prognostic value in localized SCCA (Cabel, Clin Cancer Res 2018 in press). This ancillary study reports the impact of HPV ctDNA detection in patients enrolled in the Epitopes-HPV02 trial.


Per protocol, serum samples (1 ml) were collected twice: before CT and, in non-progressive patients, at CT discontinuation which occurred after 5 months on CT. HPV16 ctDNA was quantified by ddPCR at both time points and correlated with prospectively registered patient characteristics and outcomes; for post-CT survival analyses, a landmark was set at the time of CT discontinuation.


Among 59 patients with HPV16+ advanced SCCA, 52 (88%) had ctDNA detected at baseline (sensitivity: 91.1%; 95%CI[81.1;96.2]) with a median level of 7,148 copies/ml (range: 8.3- 3,147,000). Baseline ctDNA levels were not associated with any of the patient characteristics; ctDNA level below the median at baseline was correlated with a longer PFS (HR = 2.6, 95%CI[1.1;5.9], p = 0.02). Among 38 patients who completed the 5 months CT, residual ctDNA after CT was detected in 14 patients (36.8%; 95%CI[23.4;52.7]) with a median level of 2,662 copies/ml (range: 31.5–211,950). Residual ctDNA detected at CT discontinuation was strongly associated with shorter post-CT PFS (measured from the time of CT discontinuation, median PFS: 5.4 months vs not reached; HR = 6.2, 95%CI[2.3;16.3], p < 0.001) and OS (HR = 9.6, 95%CI[2.0;46.9], p = 0.005).


In this prospective study in advanced SCCA, we observed a strong prognostic impact of HPV ctDNA before 1st line CT and, in non-progressive patients, after 6 months of DCF. With a limited cost and short turnaround, this quantitative assay is a promising tool to optimize the therapeutic management of SCCA with e.g. maintenance anti PD-1/PD-L1 therapy in ctDNA-positive patients after the completion of first line CT.

Clinical trial identification


Legal entity responsible for the study

Institut Curie.


Fondation ARC.

Editorial Acknowledgement


T. André: Honoraria and advisory role: Roche, BMS, Merck & Co. E. Samalin: Honoraria: Sanofi, Bayer, Servier, Roche; Study support: Merck, Bayer; Congress support: Roche, Ipsen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.